• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Development of novel therapeutic approaches in ischemic stroke targeting regulation of inflammation through RANKL/RANK signal

Research Project

Project/Area Number 25462214
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field Neurosurgery
Research InstitutionOsaka University

Principal Investigator

Munehisa Shimamura  大阪大学, 医学(系)研究科(研究院), 寄附講座准教授 (60422317)

Co-Investigator(Kenkyū-buntansha) KURINAMI HITOMI  大阪大学, 大学医学部附属病院, 助教 (10638555)
Project Period (FY) 2013-04-01 – 2016-03-31
Project Status Completed (Fiscal Year 2015)
Budget Amount *help
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Keywords脳梗塞 / マクロファージ / ミクログリア / 炎症 / RANKL / RANK / OPG
Outline of Final Research Achievements

In the present study, we examined the possibilities of a novel therapy using recombinant RANKL (rRANKL) in ischemic stroke model in mice. The optimal dose of rRANKL for preventing exacerbation of stroke size and inflammation was 5 ng i.c.v. or 1 μg s.c. with repetitive injections, whose therapeutic window was 6 hrs after the insult.Expression of inflammatory cytokines was also inhbitted in rRANKL-treated mice. However, we found that another group showed repetitive systemic injections of rRANKL caused osteoporotic changes in bone in mice. To avoid the side effects, we tried intranasal injection of rRANKL to achieve direct delivery of rRANKL in brain. rRANKL was successfully delivered to brain, but the therapeutic effects were not shown probably due to insufficient amount of delivered rRANKL. Thus, therapeutic application of rRANKL has been shown to be possible in intracerebroventricular injection or systemic injection with some modifications, which do not activate osteoclast.

Report

(3 results)
  • 2015 Annual Research Report   Final Research Report ( PDF )
  • 2013 Research-status Report
  • Research Products

    (5 results)

All 2015 2014

All Presentation (4 results) Patent(Industrial Property Rights) (1 results)

  • [Presentation] 脳梗塞後の炎症を制御するRANKL-RANKシグナルについての検討2015

    • Author(s)
      島村宗尚
    • Organizer
      第21回国際個別化医療学会
    • Place of Presentation
      大阪
    • Year and Date
      2015-10-17
    • Related Report
      2015 Annual Research Report
  • [Presentation] RANK シグナルをターゲットにした脳梗塞における新規治療法についての検討2015

    • Author(s)
      島村宗尚
    • Organizer
      第6回日本脳血管・認知症学会学術大会
    • Place of Presentation
      東京
    • Year and Date
      2015-09-19
    • Related Report
      2015 Annual Research Report
  • [Presentation] RANKL-RANK is a novel anti-inflammatory signaling system in ischemic brain2015

    • Author(s)
      島村宗尚
    • Organizer
      第56回日本神経学会学術大会
    • Place of Presentation
      新潟
    • Year and Date
      2015-05-20
    • Related Report
      2015 Annual Research Report
  • [Presentation] Role of OPG/RANKL/RANK System in Ischemic Brain in Mice.2014

    • Author(s)
      Munehisa Shimamura
    • Organizer
      International Stroke Meeting 2014
    • Place of Presentation
      San Diego(アメリカ)
    • Related Report
      2013 Research-status Report
  • [Patent(Industrial Property Rights)] 梗塞性疾患の予防または治療用医薬2014

    • Inventor(s)
      島村宗尚
    • Industrial Property Rights Holder
      島村宗尚
    • Industrial Property Rights Type
      特許
    • Filing Date
      2014
    • Related Report
      2013 Research-status Report

URL: 

Published: 2014-07-25   Modified: 2019-07-29  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi